CARDIOVASCULAR SYSTEMS INC 4

4 · CARDIOVASCULAR SYSTEMS INC · Filed Feb 25, 2009

Form 4

Period: 2009-02-25

Director

Transactions

Other
Warrant
2009-02-25+87,416→ 87,416 total(indirect: By LLC)
Exercise: $5.71From: 2009-02-25Exp: 2014-02-24→ Common Stock (87,416 underlying)

Holdings

Common Stock
(indirect: By LLC)
151,167
Common Stock
60,000
Stock Option (right to buy)
Exercise: $6.00From: 2004-12-01Exp: 2009-11-30→ Common Stock (10,000 underlying)
10,000
Stock Option (right to buy)
Exercise: $8.00From: 2005-12-01Exp: 2010-11-30→ Common Stock (15,000 underlying)
15,000
Stock Option (right to buy)
Exercise: $5.71From: 2006-12-19Exp: 2016-12-18→ Common Stock (20,000 underlying)
20,000
Stock Option (right to buy)
Exercise: $5.11From: 2007-10-09Exp: 2017-10-08→ Common Stock (6,681 underlying)
6,681
Stock Option (right to buy)
Exercise: $7.36From: 2007-11-13Exp: 2017-11-12→ Common Stock (23,319 underlying)
23,319
Series A Conv Preferred Stock
(indirect: By LLC)
→ Common Stock (132,042 underlying)
132,042
Series A-1 Conv Preferred Stock
(indirect: By LLC)
→ Common Stock (43,235 underlying)
43,235
Series B Conv Preferred Stock
(indirect: By LLC)
→ Common Stock (54,585 underlying)
54,585
Warrant
(indirect: By LLC)
Exercise: $5.71From: 2006-07-19Exp: 2011-07-19→ Series A Conv Preferred Stock (18,750 underlying)
18,750
Warrant
(indirect: By LLC)
Exercise: $6.00From: 2008-09-12Exp: 2013-09-12→ Common Stock (83,333 underlying)
83,333

Footnotes (5)

[F1]Shares are held by GDN Holdings, LLC, of which Dr. Nelson is the sole owner.
[F2]Each share of Series A convertible preferred stock is convertible at any time, at the holder's election, into 1.01 shares of common stock and has no expiration date.
[F3]Each share of Series A-1 convertible preferred stock is convertible at any time, at the holder's election, into 1.03 shares of common stock and has no expiration date.
[F4]Each share of Series B convertible preferred stock is convertible at any time, at the holder's election, into 1.01 shares of common stock and has no expiration date.
[F5]Holders of approximately 68% of the outstanding preferred stock entered into an agreement with the Company whereby effective immediately prior to the effective time of the merger of the Company with Replidyne, Inc., all preferred stock will convert into shares of common stock. The warrants were issued pro rata to each preferred shareholder, based on the percentage of preferred stock held, in consideration for entering into such conversion agreement.

Documents

1 file